Background: Reverse remodeling (RR) after cardiac resynchronization therapy (CRT) is associated with favorable clinical outcomes in heart failure (HF). The renin-angiotensin-aldosterone system (RAAS) is involved in the remodeling process.
Reverse remodeling (RR) of dilated failing ventricles is a generally accepted goal in the treatment of heart failure (HF). RR can be obtained by medical therapy, as demonstrated by the landmark randomized controlled trials of renin-angiotensin-aldosterone system (RAAS) inhibitors and beta-blockers. More recently, cardiac resynchronization therapy (CRT) has also been shown to trigger RR in patients with advanced HF and dyssynchrony, even when on optimal medical treatment. Besides improving clinical symptoms, quality of life, exercise tolerance, and survival in patients with advanced HF, 1, 2 CRT reverses the remodeling process by reducing ventricular size, mass, and mitral regurgitation in both short and long terms. 3e5 RR, as defined by decreases in left ventricular end-systolic volume (LVESV) compared with preprocedural values, peaks on average within 6 months after CRT and has been associated with better clinical outcomes. 3,6e8 Failure of RR after CRT is therefore an important clinical issue with relevant prognostic implications. Demographic, clinical, and procedural variables have been associated with RR after CRT, 9e15 but no data are available currently on the possible association of genetic variants with an RR phenotype.
The RAAS plays a major role in the pathophysiology of HF, through increased vasoconstriction, sodium and water retention, myocardial fibrosis, and ventricular remodeling, and is a generally accepted therapeutic target in HF. Using the candidate gene approach, genetic variance in the RAAS has been previously associated with left-ventricular hypertrophy, remodeling or HF (susceptibility genes), or other specific phenotypic expressions (modifier genes). 16, 17 We assessed, using a multicenter case-control design, the prevalence of genetic variants in 6 RAAS genes that play pivotal roles in cardiovascular function or signal transduction and that most likely affect the RR process in patients with chronic systolic HF and different degrees of reverse left ventricular (LV) remodeling after CRT.
Methods

Study Population
Out of a total population of 1,421 patients implanted with CRT since 2002 at the 3 participating institutions, we enrolled 160 consenting subject who had undergone CRT $12 months earlier and were consecutively reviewed in the electrophysiology outpatient clinics of the 3 participating institutions from March to December 2009. CRT had been performed in all according to current guidelines, 18 ie, advanced heart failure (New York Heart Association [NYHA] functional class IIeIV), wide QRS complex ($120 ms), depressed LV function (ejection fraction [LVEF] #35%), and LV end-diastolic diameter O55 mm at baseline, through transvenous implantation of a right ventricular defibrillation lead, an atrial pacing lead (except for patients in atrial fibrillation), and a coronary sinus lead for LV pacing. Entry criteria also included stable positioning of the left lead at the lateral or posterolateral wall level and ventricular volumes measured at follow-up echocardiography 6e12 months after CRT. Patients with procedural failure, particularly a nonfunctioning LV lead, were excluded.
Lack of reverse remodeling (RRÀ) was defined as any change in LVESV at follow-up echocardiography, 6e12 months after CRT OÀ15% compared with baseline values. For each RRÀ patient, a control subject with LVESV decrease O15% (RRþ) matched by sex, NYHA functional class, HF etiology, age (within 10 years), and baseline LVEF (within 5%) was enrolled.
Blood was sampled for genetic analysis during a follow-up outpatient visit. Timing of data collection was baseline, ie, the last available data before CRT, and follow-up, ie, 6e12 months after the procedure.
The study was approved by the Institutional Ethics Committees of the 3 participating centers. Patients expressed their written informed consents to participate.
Genotyping
The selected common variants within 6 RAAS genes have been replicatively associated with HF phenotypes 16 and were considered as markers and/or functional variants. For the ACE gene, we included 3 variants, because linkage and association analysis suggested their combinations to be better predictors for angiotensin-converting enzyme (ACE) protein levels than either one alone. 19 We included only variants with previously reported minor allele frequencies of O10% in a European ancestry population.
Genomic DNA was extracted from 200 mL of patients' EDTA blood with the use of the QIAamp DNA Blood kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Genotyping was performed at the University Clinic of M€ unster, Germany, blinded to remodeling status, with the use of TaqMan SNP Genotyping Assays. Assays were purchased from Applied Biosystems (Life Technologies Corporation, Carlsbad, California, USA) and were applied using the ABI7900 real-time polymerase chain reaction (PCR) system. Real-time PCR was performed in a 384-well format with the use of 2.5 mL TaqMan Genotyping Master Mix (2Â), 0.125 mL TaqMan SNP Genotyping Assay (40Â), 2.375 mL DNase-free water, and 2 ng DNA. Real-time PCR conditions were as follows: initial denaturing at 95 C for 10 minutes, 40 cycles of 95 C for 15 seconds, and 60 C for 1 minute. Replicate samples and samples without template were used as control.
From the original population of 160 subjects from whom blood was sampled, successful genotyping was available for 156 patients.
Echocardiographic Measurements
All patients underwent a comprehensive transthoracic echocardiographic examination at rest, with the use of conventional methods using commercially available ultrasound machines equipped with a 2.5e3.5-MHz phased-array sector scan probe, second harmonic technology. LV volumes were measured and LVEF obtained by 2-and 4-chamber view (Simpson's rule). Intra-and interoperator variabilities for volume measurements were 5% and 6%, respectively.
Statistical Analysis
Data are expressed as median and interquartile range and frequency (%). Chi-square test was used to compare categoric variables, or the Fisher exact test if necessary, with Mantel-Haenszel linear-by-linear association where appropriate. Student t test or Mann-Whitney test was used to compare continuous variables. The correlation between changes in LVESV and LVEF was investigated by Spearman correlation and presented by r and P values. Concordance between RR criteria derived from LVESV or LVEF changes was assessed by the k statistic.
Genotyping call rates were all O98%. Hardy-Weinberg equilibrium was tested by calculating the expected genotype frequencies from the allele frequencies; deviation from the observed genotype frequencies was determined by chi-square. Genotype distributions in the 6 RAAS pathway genes analyzed were compatible with Hardy-Weinberg equilibrium, except for rs1403543 polymorphism in the AGTR2 (angiotensin receptor 2) gene, which was consequently dropped from further analysis, leaving 5 genes and 7 SNPs to be tested for association with RR (Table 1 ). Genetic association was tested by comparing allelic frequencies between RRÀ and RRþ groups. To correct for multiple comparisons, we used the Benjamini and Yekutieli false discovery rate method. 20 Statistical significance was declared at P # .0193 using the formula P 5 a/S(1/i), where a 5 .05 and i ranges from 1 to N, where N 5 7 represents the number of allele comparisons.
Group sample sizes of 76 RRÀ and 80 RRþ achieve O80% power to detect an allele frequency difference of 0.10 (odds ratio [OR] 2.58) for an allele of 11% population frequency.
The association between lack of RR and genetic variants was adjusted for clinically relevant potential confounders by multivariable logistic regression. Odds ratios with their corresponding 95% confidence intervals (CIs) were estimated. Hosmer-Lemeshow U-statistic was calculated as a measure of fit.
Two-sided P values of !.05 were considered to be statistically significant. The Statistical Package for the Social Sciences (SPSS) v17 was used for all analyses.
Results
Characteristics of RR Table 2 shows the preprocedural clinical characteristics of the study population. LVESV changes were assessed at follow-up 9 (7e12) months after CRT, compared with the preprocedural echocardiogram. Eighty patients were classified as RRþ and 76 as RRÀ. The 2 groups were well matched by baseline clinical characteristics, except for prevalence of diabetes (RRÀ 24% vs RRþ 11%; P 5 .06).
After CRT, both LV volumes decreased and LVEF improved significantly in RRþ, whereas they were unchanged in RRÀ (Fig. 1) . As expected, changes from baseline to follow-up in LVESV and LVEF were correlated (Spearman r coefficient 5 À0.72; P ! .001). Concordance between the 15% decrease LVESV cutoff and improved LVEF was moderate: k value was 0.56 (P ! .001) for an absolute 5% LVEF increase and 0.43 (P ! .001) for a 15% relative LVEF increase. At follow-up (Table 3) , a significantly greater proportion of RRþ than of RRÀ subjects improved by at least 1 NYHA functional class (75% vs 55%; P ! .01), whereas no differences were observed in drug treatment between groups.
RAAS Variants and RR
Allele frequencies of the 7 analyzed SNPs are shown in Table 4 . Only the minor (C) allele frequency of the NR3C2 gene, encoding the mineralocorticoid receptor (MR), was significantly higher in RRÀ than in RRþ. After CRT, LVESV decreased significantly less in carriers of NR3C2 minor allele (P 5 .02; Fig. 2) . Conversely, the NR3C2 minor C allele was associated with a graded lesser extent of RR (P 5 .0008; Fig. 3 ).
MR antagonist treatment conditions did not differ between carriers of the minor allele and noncarriers: Administration rates were 67% vs 61% (P 5 .09), and daily doses LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MR, mineralocorticoid receptor; NYHA, New York Heart Association; RAAS, renin-angiotensin-aldosterone system; RR, reverse remodeling.
Values are expressed as n (%) or median (interquartile range).
were 25 (25e37) mg vs 37 (25e50) mg (P 5 .22), respectively. By multivariable logistic regression, after adjustment for age, sex, previous myocardial infarction, NYHA functional class, atrial fibrillation, baseline LVEF, and diabetes, presence of the minor allele in the NR3C2 gene remained independently associated with lack of RR during follow-up (Table 5) . The model showed good calibration (Hosmer-Lemeshow goodness of fit statistic: P 5 .95).
Discussion
To the best of our knowledge, this is the first report on the role of variants in candidate genes linked to cardiac structure and function in LV remodeling response after CRT. The main finding of our study that excluded subjects with procedural failure is the association between lack of RR after CRT and the minor allele of the NR3C2 gene involved in aldosterone signaling, even after adjustment for known clinical confounders.
RR occurs in more than one-half of patients and peaks between 6 and 12 months after CRT. Its prevalence varies with the echocardiographic variable and cutoff chosen and timing of assessment. 6, 7, 21, 22 We used LVESV decrease as marker of RR because of its reported association with outcomes, and selected the more stringent cutoff of 15%, rather than the 10% criterion coupled to survival at 6 months, because by definition all of our patients were alive at the time of genetic characterization. Consistent with previous findings, 22 we observed only moderate agreement between LVESV and LVEF remodeling cutoff values. However, RRþ showed a significantly greater LVEF improvement than RRÀ (Fig. 1) .
In our white population, which is representative of other series of HF patients on optimized medical treatment undergoing CRT, 51% of the subjects showed a LVESV decrease of O15% at a median time of 9 months after the procedure. The observed balance between RRÀ and RRþ in acknowledged key clinical predictors of outcome dims their confounding effect and minimizes bias in the evaluation of genetic variance. Factors underlying response to CRT regarding RR are probably many, and among them patients' genetics may well have a role. 23 RRÀ patients had a higher prevalence of diabetes of borderline significance. Several reports have focused on the impact of diabetes on response to CRT. 24, 25 Intriguingly, all of our diabetic patients carrying the minor allele of the NR3C2 gene had an RRÀ phenotype, but the association was not confirmed after adjustment for clinical confounders, including previous myocardial infarction.
Because the scope of our investigation was restricted to patients in whom technically successful CRT was not followed by improved chamber size and pump function, we investigated RAAS genetic variants linked to altered protein function and ventricular structure. In this population, only Abbreviations as in Table 2 .
the rs5522 polymorphism of the NR3C2 gene was significantly associated with lack of RR, suggesting its possible modifier effect on the putative mechanisms of structural change.
The deleterious role of aldosterone and MR activation in the heart has recently been extensively reviewed. Aldosterone induces hypertrophy and the dysregulation of proliferation and apoptosis in the myocardium and vessel wall, which lead to fibrosis and chamber remodeling. MR activation, by changes in redox status or by aldosterone levels inappropriate for sodium status, is accompanied by vascular inflammation and end-organ damage. Deletion of MR in cardiomyocytes ameliorates adverse remodeling after myocardial infarction in the rodent model. 30 In clinical trials in both advanced and mild HF, 31 MR antagonists at doses devoid of relevant natriuretic effects improved mortality and morbidity, despite plasma aldosterone levels in the low to normal range. The adverse effects of MR stimulation may in fact be independent from peripheral hormone concentrations. In the Framingham Offspring Study, 32 there was no association between plasma aldosterone levels and variants in the MR and aldosterone synthase genes, with an estimated heritability of serum aldosterone of 0.10. In the RALES (Randomized Aldactone Evaluation Study) trial, 25 mg spironolactone had no apparent effect on sodium retention score, urinary sodium excretion, or body weight but was associated with reduced mortality and morbidity.
The negative effects of aldosterone on myocardial tissue might be mediated by genetically modulated increased activity of the MR receptor. The independent association between NR3C2 minor allele and RRÀ phenotype in the present population suggests that this genetic variant might result in MR up-regulation, heightened susceptibility even to normal aldosterone levels, adverse changes in extracellular matrix, and a lower probability of favorable CRT effects.
Study Limitations
The population studied in this pilot investigation, although phenotypically well characterized and balanced across many clinical confounders, was retrospectively enrolled, relatively small, and possibly not adequately powered to detect even small phenotypic differences for all genetic variants studied. However, we used stringent phenotypic criteria for RR that had previously been validated through hard end points of morbidity and mortality 6e8 and restricted our analysis to genes with reported minor allele frequencies of O10% in a population with European ancestry. Del, deletion; Ins, insertion; other abbreviations as in Tables 1 and 2 . *Significance level after false discovery rate correction: !.0193. We did not assess plasma aldosterone levels or urinary sodium excretion. However, the functional effects of the polymorphism on plasma aldosterone levels may be particularly difficult to elucidate in HF patients on optimal drug therapy. In severe HF, plasma aldosterone concentrations are elevated and correlate with resistance to loop diuretics. Even under effective pharmacologic RAAS blockade with ACE inhibitors, aldosterone breakthrough occurs in a substantial proportion of HF patients with return to pretreatment plasma hormone levels 32 so large as to overcome possible differences in gene products due to polymorphisms. On the other hand, it is conceivable that biomarkers may exist that differentially interact with genotypes on phenotype expression.
Clinical Implications
The genetic findings of this pilot investigation are directly tied to the biology underlying the remodeling process. Candidate genes of the RAAS have multiple lines of evidence to support a possible role in a lack of RR: the NR3C2 polymorphism is involved in aldosterone signaling in the myocardium and vascular wall, and blockade of the MR prevents progression of cardiac damage in the experimental model and in human disease. Nonetheless, our findings remain largely speculative unless they are proved in larger series. In particular, the role of pharmacogenomic profiling to tailor levels of aldosterone blockade requires careful investigation in adequately powered samples to account for different confounders and dosing. For this purpose, well designed registries 33 or biobanks from randomized controlled trials may prove to be more suitable.
Conclusion
Lack of RR after CRT was linked in the present series to genetic variants involved in aldosterone signaling that have been previously associated with cardiovascular phenotypes. Whether genetic characterization might better identify HF patients who may be most likely to benefit from device implantation deserves further investigation. Abbreviations as in Tables 1 and 2. 
